Navigation Links
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Date:10/30/2010

rates," said Stefan Zeuzem, MD, Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany and lead investigator of the study. "An interferon-sparing regimen could provide an important treatment option for patients with chronic hepatitis C."Proportion of patients with viral load <25 IU/mlDay 8Day 15Day 22Day 29400mg TID BI 207127 + BI 201335 + RBV

4/15

6/15

10/15

11/15600mg TID BI 207127 + BI 201335 + RBV

3/17

14/17

17/17

17/17The PegIFN sparing treatment was well tolerated. Investigators reported that the most common adverse events observed in the study were mild gastro-intestinal effects (diarrhea, nausea, vomiting), rash or photosensitivity. Laboratory parameters did not indicate any relevant changes from baseline, except for a continuous drop in amino alanine transferase (ALT) in all patients, a decrease of hemoglobin (median -1.7 and -2.6 g/dL) and an increase of unconjugated bilirubin (median +9.8 and +11.5 umol/L) similar to reported results from earlier BI 201335 trials. There were no serious or severe adverse events and no discontinuations due to adverse events reported in the study during treatment with BI 207127 and BI 201335. A phase IIb trial testing different dose regimens of this combination with longer durations is planned to evaluate sustained virological response rates.

Additional studies to be presented at AASLD

  • Virological response and safety of 4 weeks treatment with the protease inhibitor BI 201335 combined with 48 weeks of peginterferon alpha 2a and ribavirin for treatment of HCV GT-1 patients who failed peginterferon / ribavirin
    (Poster 804. T. Berg, et al. Sun, October 31 - 8:00 AM. Hynes: Exhibit Hall C)

  • Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with
    '/>"/>


  • SOURCE Boehringer Ingelheim Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
    3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    5. Tapestry Reports Second Quarter 2007 Results
    6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... The Canadian Epilepsy Alliance (CEA) is thrilled to announce the ... about the most common neurological disorder in Canada ... series tells a fictional story based on the experiences of ... epilepsy. "Despite the fact that epilepsy affects ... and lack of awareness out there," says Gail Dempsey ...
    (Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ...  physicians in Brazil and ... clinical guidelines and commonly prescribe long-acting beta-agonist (LABA)- ... they do so within current severe cost/coverage constraints. ... that are expected to launch in these countries—which ...
    (Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- Inc. magazine ... the third straight year, No. 349 in Health ... ranking of the nation,s fastest-growing private companies. The ... most important segment of the economy—America,s independent entrepreneurs. ... Pizza, LinkedIn, Zillow, and many other well-known names ...
    Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
    ... Jan. 26, 2012  The National Basketball Association (NBA), the ... League (NBA D-League), in collaboration with the American Diabetes ... year of the Dribble to Stop Diabetes ... to live an active, healthy lifestyle and raise awareness ...
    ... Spine, Inc. today announced the FDA clearance of ... (Logo: http://photos.prnewswire.com/prnh/20100419/LA88318LOGO )  ... unparalleled percutaneous access to the disc space, the ... Interventional Spine,s revolutionary PerX360 System™. This is the ...
    Cached Medicine Technology:NBA, American Diabetes Association and Sanofi US Tip Off 2012 Dribble to Stop Diabetes Campaign 2NBA, American Diabetes Association and Sanofi US Tip Off 2012 Dribble to Stop Diabetes Campaign 3NBA, American Diabetes Association and Sanofi US Tip Off 2012 Dribble to Stop Diabetes Campaign 4Interventional Spine, Inc. Announces FDA Clearance of its Opticage™ Expandable Interbody for Treatment of Degenerative Disc Disease 2
    (Date:8/21/2014)... According to the new report “Waterborne ... Polyurethane, PTFE, PVDF, PVDC, & Others), by Application ... Coil, & Others) - Global Forecast to 2019” ... is estimated to reach $77,838.71 Million by 2019. ... figures spread through 225 Slides and in-depth TOC ...
    (Date:8/21/2014)... Indiana (PRWEB) August 21, 2014 ... employee benefits advisory organization, is pleased to announce ... Based in Knoxville, Tennessee, Trinity Benefit Advisors ... close, long-term relationships with their clients. Their consultative ... planning and objective setting, implementation, and monitoring. Their ...
    (Date:8/21/2014)... Competing in the “Best TV show” category, ... on Monday, August 25th at 7 pm at the ... festival is named in top festival lists and is ... Avid, and Write Brothers. , The event will occur ... at 410 South Myrtle Avenue (showtimes: 626-305-SHOW; email: monrovia(at)kptmovies(dot)com). ...
    (Date:8/21/2014)... 21, 2014 Home Care Assistance ... today announced that it has received the Certified – ... illustrates Home Care Assistance’s commitment to client satisfaction. , ... that our client’s in the South Metro Denver area ... Lane, Owner of Home Care Assistance of Centennial. ...
    (Date:8/21/2014)... York (PRWEB) August 21, 2014 According ... Research "Enteral Feeding Devices Market (Enteral Feeding Tubes, Enteral ... - Global Industry Analysis, Size, Share, Growth, Trends and ... was valued at USD 2.0 billion in 2012 and ... 3.1 billion in 2019growing at a CAGR of 6.2% ...
    Breaking Medicine News(10 mins):Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 4Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:“Heavy Metal Greg,” a Music Talk Show by Gregory Graham, Will Screen at Action on Film International Film Festival on 08/25/2014 2Health News:Home Care Assistance of Centennial Receives Home Care Pulse Certified – Trusted Provider Distinction 2Health News:Home Care Assistance of Centennial Receives Home Care Pulse Certified – Trusted Provider Distinction 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
    ... Cancers and Colorectal Screening Among Key ProvisionsBETHESDA, Md., ... and its more than 10,000 physician members congratulate ... today for the introduction of "21st Century Cancer ... Treatment) Act" and their vow to renew the ...
    ... The ,Help is Here Express, bus tour will be ... 3 at various cities throughout the state in order ... programs that provide prescription medicines for free or nearly ... exceeding that of the nation (8.1 percent), the Partnership ...
    ... 26 BioMosaics Inc., a cancer biomarker ... antibody product (clone 1G12) for detection of ... as an immunohistochemical test for diagnosis of ... Laboratories is a state-of-the-art reference pathology laboratory ...
    ... average sodium intake far exceeds recommendations, raising health risks, ... American consumes far more salt each day than is ... from the U.S. Centers for Disease Control and Prevention ... high blood pressure, blacks, and middle-age and older adults ...
    ... new study by researchers at the University of British Columbia ... The study, published in the Journal of Public Health ... three times more likely than those who don,t to meet ... of physical activity. , Doctoral student Ugo Lachapelle and Assoc. ...
    ... Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: ... completed its acquisition of Genentech pursuant to a short-form ... the Roche Group. Roche had announced earlier in the ... expired on Wednesday, March 25. In connection with the ...
    Cached Medicine News:Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 3Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 2Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 3Health News:Using Too Much Salt Is Common in U.S., CDC Says 2Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:Roche Completes Acquisition of Genentech 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: